TAROS CHEMICALS GMBH & CO KG

Their core work

Taros Chemicals is a Dortmund-based contract research and chemical services SME specializing in medicinal chemistry, compound library synthesis, and high-throughput screening. They provide enabling chemistry services — from custom synthesis of drug-like molecules to flow chemistry and process optimization — primarily serving pharmaceutical and biotech clients. In H2020, they contributed chemical expertise to training networks focused on antibiotic discovery, protein-protein interaction modulators, and advanced synthesis technologies.

What they specialise in

How they've shifted over time

Taros's early H2020 work (2015-2017) centered on classical medicinal chemistry — providing compound synthesis for drug target validation in antibacterials and protein-protein interactions. By 2018, their focus shifted toward advanced enabling technologies: flow chemistry, 3D-printing for chemical synthesis, organocatalysis, and photocatalysis (TECHNOTRAIN), alongside large-scale compound library curation for biological screening (ESCulab). This evolution suggests a deliberate move from pure bench chemistry toward technology-driven, automated synthesis methods.

Taros is moving from traditional contract synthesis toward technology-enabled chemistry (flow, automation, photocatalysis), positioning itself as a partner for projects that need modern, scalable synthesis infrastructure.

How they like to work

Taros participates exclusively as a partner, never as coordinator — consistent with an SME providing specialized chemistry services within larger academic-led consortia. With 39 unique partners across 13 countries from just 4 projects, they operate in large, multinational training networks and research alliances. This pattern suggests they are a trusted service provider that research groups bring in when they need professional compound synthesis and screening capabilities.

Taros has built a broad European network of 39 partners across 13 countries through just 4 projects, indicating participation in large MSCA training networks with wide geographic spread. Their connections are predominantly in the academic pharmacology and chemistry training space.

What sets them apart

Taros occupies a specific niche: they are a private SME that bridges the gap between academic drug discovery and industrial chemistry. Unlike university labs, they offer professional compound library management and contract synthesis with commercial reliability. Their combination of medicinal chemistry expertise with emerging flow and automated synthesis technologies makes them a practical partner for consortia that need real-world chemical production capabilities alongside academic research.

Highlights from their portfolio

• ESCulab
  Largest funding (EUR 292,600) and their only Health-pillar project, contributing to a European-scale screening centre with unique compound libraries for biological assays.
• TECHNOTRAIN
  Represents their strategic pivot toward enabling technologies — flow chemistry, 3D-printing, photocatalysis — signaling future direction of their capabilities.
• INTEGRATE
  Addressed the critical public health challenge of Gram-negative antibiotic resistance, demonstrating Taros's relevance to infectious disease drug discovery.